Indications
Denosis is a RANK ligand (RANKL) inhibitor indicated for:Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Denosis is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of ... Read moreDenosis is a RANK ligand (RANKL) inhibitor indicated for:Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture: Denosis is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Denosis reduces the incidence of vertebral, nonvertebral, and hip fractures.Treatment to Increase Bone Mass in Men with Osteoporosis: Denosis is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.Treatment of Glucocorticoid-Induced Osteoporosis: Denosis is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Denosis is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Denosis also reduced the incidence of vertebral fractures.Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer: Denosis is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.Treatment of Multiple Myeloma and Bone Metastasis from Solid Tumors: Denosis is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.Treatment of Giant Cell Tumor of Bone: Denosis is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.Treatment of Hypercalcemia of Malignancy: Denosis is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL. It binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By binding RANKL, denosumab prevents it from activating its receptor, RANK, on the surface of osteoclasts and their precursors. This blocks the RANKL/RANK interaction, inhibiting osteoclast formation, function, and survival. As a result, bone resorption decreases while bone mass and strength increase in both cortical and trabecular bone.
Pregnancy & Breastfeeding
Pregnant women and females of reproductive potential: Denosumab may cause fetal harm when given during pregnancy. Females of reproductive potential should be advised to use effective contraception during treatment and for at least 5 months after the last dose of Denosumab.
Lactation: Whether to breastfeed while using Denosumab should take into account the developmental and health benefits of breastfeeding, the mother's clinical need for Denosumab treatment, and any potential adverse effects on the breastfed child from Denosumab itself or from the underlying maternal condition.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.